高级搜索

CEACAM6表达与食管鳞癌免疫浸润及不良预后的关联

CEACAM6 Expression is Associated with Immune Infiltration and Poor Prognosis in Esophageal Squamous Cell Carcinoma

  • 摘要:
    目的 探讨癌胚抗原相关细胞黏附分子6(CEACAM6)在食管鳞状细胞癌(ESCC)中的表达,及其与肿瘤免疫细胞浸润和患者预后的相关性。
    方法 基于GEO数据库中的三个ESCC数据集(GSE161533、GSE26886、GSE23400),筛选差异表达基因并通过生存分析确定关键基因CEACAM6。利用TIMER等数据库,分析CEACAM6在ESCC中的表达、预后价值及其与免疫细胞浸润的关系。进一步收集162例ESCC患者组织样本,采用免疫组织化学法检测CEACAM6、免疫细胞标志物(CD4、CD8、CD20、CD56)及免疫检查点分子(HHLA2、CD40LG)的表达,分析CEACAM6表达与临床病理特征、免疫细胞浸润及相关免疫检查点表达的关系。
    结果 生物信息学分析与临床样本验证均表明,CEACAM6在ESCC组织中的表达显著高于癌旁组织(P<0.05)。CEACAM6高表达与晚期临床分期(AJCC Ⅲ~Ⅳ期)、T分期(T3~T4)、淋巴结转移、非溃疡型病理特征及患者不良预后密切相关。此外,CEACAM6表达水平与肿瘤微环境中CD8+ T细胞、CD4+ T细胞、CD20+ B细胞的浸润密度,以及免疫检查点分子HHLA2和CD40LG的表达均呈正相关(均P<0.05)。
    结论 CEACAM6是ESCC的独立不良预后因素,其高表达与特定免疫细胞浸润及免疫检查点分子表达相关,揭示其可能参与肿瘤免疫微环境调控,有望成为ESCC潜在的预后生物标志物及免疫治疗新靶点。

     

    Abstract:
    Objective To investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in esophageal squamous cell carcinoma (ESCC) and analyze its correlation with immune cell infiltration and patient prognosis.
    Methods Three ESCC datasets (GSE161533, GSE26886, and GSE23400) from the GEO database were analyzed to identify differentially expressed genes. CEACAM6 was identified as a key gene through survival analysis. Its expression, prognostic value, and relationship with immune cell infiltration were further explored using databases, such as TIMER. Tissue samples were collected from 162 patients with ESCC. Immunohistochemistry was performed to detect the expression of CEACAM6, immune cell markers (CD4, CD8, CD20, and CD56), and immune checkpoint molecules (HHLA2 and CD40LG). Correlations between CEACAM6 expression and clinicopathological features, immune cell infiltration, and immune checkpoints were analyzed.
    Results Bioinformatic analysis and clinical sample validation confirmed that CEACAM6 expression was significantly upregulated in ESCC tissues compared with adjacent nontumor tissues (P<0.05). High CEACAM6 expression was closely associated with advanced clinical stage (AJCC Ⅲ-Ⅳ), high T stage (T3-T4), lymph node metastasis, nonulcerative type, and poor prognosis. Furthermore, CEACAM6 expression levels were positively correlated with the infiltration density of CD8+ T cells, CD4+ T cells, and CD20+ B cells within the tumor microenvironment and with the expression of the immune checkpoint molecules HHLA2 and CD40LG (all P<0.05).
    Conclusion CEACAM6 serves as an independent poor prognostic factor for ESCC. Its high expression is implicated in the modulation of the tumor immune microenvironment by correlating with specific immune cell infiltration and immune checkpoint molecules, suggesting its potential as a novel prognostic biomarker and immunotherapeutic target for ESCC.

     

/

返回文章
返回